Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis

[EN] To date, anti-tumor necrosis factor alfa (anti-TNF-α) therapy is the only alternative to nonsteroidal anti-inflammatory drugs for the treatment of ankylosing spondylitis. Etanercept is a soluble TNF receptor, with a mode of action and pharmacokinetics different to those of antibodies and distinctive efficacy and safety. Etanercept has demonstrated efficacy in the treatment of ankylosing spondylitis, with or without radiographic sacroiliitis, and other manifestations of the disease, including peripheral arthritis, enthesitis, and psoriasis. Etanercept is not efficacious in inflammatory bowel disease, and its efficacy in the treatment of uveitis appears to be lower than that of other anti-TNF drugs. Studies of etanercept confirmed regression of bone edema on magnetic resonance imaging of the spine and sacroiliac joint, but failed to reduce radiographic progression, as do the other anti-TNF drugs. It seems that a proportion of patients remain in disease remission when the etanercept dose is reduced or administration intervals are extended. Etanercept is generally well tolerated with an acceptable safety profile in the treatment of ankylosing spondylitis. The most common adverse effect of etanercept treatment is injection site reactions, which are generally self-limiting. Reactivation of tuberculosis, reactivation of hepatitis B virus infection, congestive heart failure, demyelinating neurologic disorders, hematologic disorders like aplastic anemia and pancytopenia, vasculitis, immunogenicity, and exacerbation or induction of psoriasis are class effects of all the anti-TNF drugs, and have been seen in patients with ankylosing spondylitis. However, etanercept is less likely to induce reactivation of tuberculosis than the other anti-TNF drugs and it has been suggested that etanercept might be less immunogenic, especially in ankylosing spondylitis. Acute uveitis, Crohn’s disease, and sarcoidosis are other adverse events that have been rarely associated with etanercept therapy in patients with ankylosing spondylitis.Senabre-Gallego, JM.; Santos-Ramírez, C.; Santos-Soler, G.; Salas-Heredia, E.; Sánchez Barrioluengo, M.; Barber, X.; Rosas, J. (2013). Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Patient Preference and Adherence. 7:961-972. doi:10.2147/PPA.S33109S961972

Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab

Llinares-Tello, F.; Gomez De Salazar, JR.; Senabre Gallego, JM.; Santos Soler, G.; Santos Ramírez, C.; Salas Heredia, E.; Molina García, J. (2012). Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab. Clinical Chemistry and Laboratory Medicine. 5(10):1845-1847. doi:10.1515/cclm-2012-00501845184751

Planck intermediate results. XXXII. The relative orientation between the magnetic field and structures traced by interstellar dust

The role of the magnetic field in the formation of the filamentary structures observed in the interstellar medium (ISM) is a debated topic owing to the paucity of relevant observations needed to test existing models. The Planck all-sky maps of linearly polarized emission from dust at 353 GHz provide the required combination of imaging and statistics to study the correlation between the structures of the Galactic magnetic field and of interstellar matter over the whole sky, both in the diffuse ISM and in molecular clouds. The data reveal that structures, or ridges, in the intensity map have counterparts in the Stokes Q and/or U maps. We focus our study on structures at intermediate and high Galactic latitudes, which cover two orders of magnitude in column density, from 1020 to 1022 cm2. We measure the magnetic field orientation on the plane of the sky from the polarization data, and present an algorithm to estimate the orientation of the ridges from the dust intensity map. We use analytical models to account for projection effects. Comparing polarization angles on and o the structures, we estimate the mean ratio between the strengths of the turbulent and mean components of the magnetic field to be between 0.6 and 1.0, with a preferred value of 0.8. We find that the ridges are usually aligned with the magnetic field measured on the structures. This statistical trend becomes more striking for increasing polarization fraction and decreasing column density. There is no alignment for the highest column density ridges. We interpret the increase in alignment with polarization fraction as a consequence of projection effects. We present maps to show that the decrease in alignment for high column density is not due to a loss of correlation between the distribution of matter and the geometry of the magnetic field. In molecular complexes, we also observe structures perpendicular to the magnetic field, which, statistically, cannot be accounted for by projection effects. This first statistical study of the relative orientation between the matter structures and the magnetic field in the ISM points out that, at the angular scales probed by Planck, the field geometry projected on the plane of the sky is correlated with the distribution of matter. In the diffuse ISM, the structures of matter are usually aligned with the magnetic field, while perpendicular structures appear in molecular clouds. We discuss our results in the context of models and MHD simulations, which attempt to describe the respective roles of turbulence, magnetic field, and self-gravity in the formation of structures in the magnetized ISM

A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac